RecruitingNot ApplicableNCT04678583
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Sponsor
Technische Universität Dresden
Enrollment
240 participants
Start Date
Jan 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Colorectal cancer with RAS mutation (KRAS or NRAS)
- Colorectal liver metastases (single or multiple)
- Planned R0 resection of liver metastases (and primary tumor, if present)
- Anatomical and non-anatomical liver resection technically feasible
- Male and female patients, age ≥ 18 years
- Written informed consent
Exclusion Criteria5
- Extrahepatic metastases
- Planned staged liver resection (e.g. two-stage hepatectomy)
- Diagnosis of another cancer \< 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer
- Expected lack of compliance
- Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
Interventions
PROCEDUREResection of colorectal liver metastases
Comparison of two liver surgery methods
Locations(37)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04678583